Literature DB >> 28422274

Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease.

C Hurabielle1, F Sicre de Fontbrune2, H Moins-Teisserenc3,4, M Robin2, M Jachiet1, T Coman2, N Dhedin2, C Cassius1, F Chasset1, A de Masson1, D Michonneau2, M Bagot1,4, A Bergeron4,5, G Socié2,4, R Peffault de Latour2,4, J-D Bouaziz1,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28422274     DOI： 10.1111/bjd.15593

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  8 in total

Review 1.  Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review.

Authors:  Han Jie Soh; Courtney Samuel; Victoria Heaton; William Douglas Renton; Angela Cox; Jane Munro
Journal:  Rheumatol Int       Date:  2019-03-05       Impact factor: 2.631

2.  Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease.

Authors:  Stephanie J Lee; Tam D Nguyen; Lynn Onstad; Merav Bar; Elizabeth F Krakow; Rachel B Salit; Paul A Carpenter; Morgani Rodrigues; A Marcie Hall; Barry E Storer; Paul J Martin; Mary E Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2017-11-10       Impact factor: 5.742

3.  Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib.

Authors:  Sa Rang Kim; Alexandra Charos; William Damsky; Peter Heald; Michael Girardi; Brett A King
Journal:  JAAD Case Rep       Date:  2018-04-30

Review 4.  Developing role of B cells in the pathogenesis and treatment of chronic GVHD.

Authors:  Xiaoping Li; Qiangguo Gao; Yimei Feng; Xi Zhang
Journal:  Br J Haematol       Date:  2018-12-26       Impact factor: 6.998

5.  Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study.

Authors:  Virginia Escamilla Gómez; Valentín García-Gutiérrez; Lucía López Corral; Irene García Cadenas; Ariadna Pérez Martínez; Francisco J Márquez Malaver; Teresa Caballero-Velázquez; Pedro A González Sierra; María C Viguria Alegría; Ingrid M Parra Salinas; Cristina Calderón Cabrera; Marta González Vicent; Nancy Rodríguez Torres; Rocío Parody Porras; Christelle Ferra Coll; Guillermo Orti; David Valcárcel Ferreiras; Rafael De la Cámara LLanzá; Paula Molés; Kyra Velázquez-Kennedy; María João Mende; Dolores Caballero Barrigón; Estefanía Pérez; Rodrigo Martino Bofarull; Silvanna Saavedra Gerosa; Jorge Sierra; Marc Poch; María T Zudaire Ripa; Miguel A Díaz Pérez; Blanca Molina Angulo; Isabel Sánchez Ortega; Jaime Sanz Caballer; Juan Montoro Gómez; Ildefonso Espigado Tocino; José A Pérez-Simón
Journal:  Bone Marrow Transplant       Date:  2019-11-07       Impact factor: 5.483

6.  JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis.

Authors:  Zhanying Hou; Xuehan Su; Guangming Han; Ruzeng Xue; Yangxia Chen; Ye Chen; Huan Wang; Bin Yang; Yunsheng Liang; Suyun Ji
Journal:  Front Med (Lausanne)       Date:  2022-06-06

7.  Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.

Authors:  Dong Wang; Yin Liu; Xiaoxuan Lai; Jia Chen; Qiao Cheng; Xiao Ma; Zhihong Lin; Depei Wu; Yang Xu
Journal:  Front Immunol       Date:  2021-06-30       Impact factor: 7.561

8.  Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis.

Authors:  Mauricio Sarmiento Maldonado; Pablo Ramírez Villanueva; Pablo Bertín Cortes-Monroy; Veronica Jara Arias; Katherine Soto Donoso; Pablo Uribe Gonzalez; Mauricio Ocqueteau Tachini; Jose Antonio Perez-Simón
Journal:  Exp Hematol Oncol       Date:  2017-12-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.